Mosqitter Turns 5,000 Mosquito Traps Into an AI Disease Surveillance Network
Mosqitter turns 5,000 chemical-free mosquito traps into an AI surveillance network globally as dengue rises and it prepares to launch Febris in November 2026.
Summary
WHO says warming, changing rainfall and global travel are widening mosquito ranges; reported dengue cases more than doubled from 6.5 million in 2023 to a record 14.6 million in 2024. Mosqitter, a 30-person Pennsylvania startup whose R&D began in Ukraine in 2019 before its 2021 commercial launch, has expanded from just over 250 devices in 2022 to more than 5,000 across five continents. Its chemical-free traps mimic human skin heat, odor, light and, in the Grand model, exhaled CO2 to catch blood-seeking females, which alone bite and lay 100 to 200 eggs roughly every three weeks.
Mosqitter now plans an AI surveillance network. Computer vision analyzes captured mosquitoes, compares neural-network identifications with external datasets and entomologist reviews, then assigns confidence scores. Weather, wind and humidity data will support forecasts of population shifts and potential health risks. The $1,999 Grand covers public and larger spaces; the $199 Mini serves homes and portable monitoring. Febris Monitoring System, planned for November 2026, adds continuous monitoring, dashboards, analytics and data services. It identifies species and associated disease potential, not whether an individual mosquito carries dengue.
Febris targets governments, health and mosquito-control agencies, airports, municipalities and universities, adding recurring revenue beyond hardware. Mosqitter manufactures and sells locally in Brazil, partners with a Greek pest-control company, sells Mini through Amazon and its U.S. website, and is deploying Febris with the U.K. Health Security Agency at Heathrow and Gatwick; India, Ukraine and Nigeria are other key markets. Co-founders CEO Anastasiia Romanova and COO Olga Diachuk seek global B2B distributors. Mosqitter expects over $1 million in 2026 revenue and projects Febris above $3.5 million in 2027 from current bids. After raising $1.9 million, it seeks $5 million in milestone-linked tranches of $1 million and $4 million.
Positives
- More than 5,000 Mosqitter devices now operate across five continents, up from just over 250 in 2022.
- Febris combines computer vision, external datasets and entomologist validation to identify mosquito species and assign confidence scores.
- Chemical-free Grand and Mini traps target biting females by mimicking human heat, odor, light and, for Grand, exhaled CO2.
- Over $1 million in expected 2026 revenue could be supplemented by more than $3.5 million from Febris in 2027.
- U.K. Health Security Agency deployments at Heathrow and Gatwick could provide continuous monitoring at major international travel hubs.
Risks & concerns
- Global dengue cases reached a record 14.6 million in 2024, more than double the 6.5 million reported in 2023.
- Febris cannot determine whether an individual mosquito carries dengue or diagnose any disease.
- The projected $3.5 million-plus Febris revenue for 2027 depends on contracts Mosqitter is still bidding on.
- Warming temperatures, changing rainfall and international travel are expanding suitable territory for disease-carrying mosquitoes.
- Mosqitter still needs to raise $5 million in two milestone-linked tranches after securing $1.9 million to date.